Podcasts

Please take our one question podcast survey!

Issue 31

Stemming the Tide: Is Long-acting, IM Octreotide Injection Better than Standard of Care for Angiodysplasia-related GI Bleeding?
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Philip Okafor, MD, MPH discuss “Standard of care versus octreotide in angiodysplasia-related bleeding: a multicenter randomized control trial,” by Goltstein L, Grooteman KV, Bernts LH et al. Gastroenterology 2024; 155: 690-703):1649-1659.

Multi-Target Stool RNA Test for Colorectal Cancer Screening: When Should You Use It?   
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Multitarget stool RNA for colorectal cancer screening,” by Barnell EK, Wurtzler EM, La Rocca J, et al. JAMA 2023; 330: 1760-68.

Can IV Metoclopramide Improve Endoscopic Visualization for Patients with Active Upper Gastrointestinal Bleeding?
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jeffrey Lee, MD, MPH discuss “The efficacy of metoclopramide for gastric visualization by endoscopy in patients with active upper gastrointestinal bleeding: double-blind randomized controlled trial,” by Vimonsuntirungsri T, Thungsuk R, Nopjaroonsri P, et al. Am J Gastroenterol 2024 May 1;119(5):846-855. PMID: 38059896.

When to Discontinue Colon Polyp Surveillance in Older Adults?
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Timothy Yen, MD discuss “Surveillance colonoscopy findings in older adults with a history of colorectal adenomas,” by Lee JK, Roy A, Jensen CD, et al. JAMA Network Open 2024; 7(4):e244611.

Issue 30

Budesonide Oral Suspension Improves Outcomes in Eosinophilic Esophagitis
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Swathi Eluri, MD, MSCR discuss “Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial,” by Hirano I, Collins MH, Katzka DA, et al. Clin Gastroenterol Hepatol. 2022 Mar;20(3):525-534.e10

Multi-Target Stool DNA Test for CRC Screening: How Accurate is the New Version?   
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Next-generation multitarget stool DNA test for colorectal cancer screening,” by T, Porter K, Zella J, et al. N Engl J Med. 2024; 390: 984-93.

Linaclotide Effective for Functional Constipation in 6-17 Year Olds: First FDA-Approved Constipation Treatment for Children
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Ahmad Abu-Heija, MBBS discuss “Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial,” by Di Lorenzo C, Khlevner J, Rodriguez-Araujo G, et al. Lancet Gastroenterol Hepatol. 2024 Mar;9(3):238-250. 

PROFILE: Can Molecular Biomarkers Predict Outcomes to Crohn’s Disease Treatment?
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Bharati Kochar, MD, MS discuss “A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial,” by Noor NM et al. Lancet Gastroenterol Hepatol. 2024; 9: 415-27

Issue 29

Cell-free DNA Blood Test for CRC Screening: A Promising Development but Won’t “Eclipse” Current Tools  
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening,” by Chung DC, Gray DM, Singh H, et al. N Engl J Med 2024; 390: 973-83.

Resmetirom Produces NASH Resolution and Decreases Fibrosis: Results from the MAESTRO-NASH Trial
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Nicole Rich, MD, MSCS discuss “A phase 3, randomized controlled trial of resmetirom in NASH with liver fibrosis,” by Harrison SA, Bedossa P, Guy CD et al. NEJM 2024; 390(6): 497-509.

How Effective Are Obesity Medications for Reducing Hepatic Decompensation in NASH?
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Sonali Paul, MD discuss “Association of Glucagon-Like Peptide-1 Receptor Agonists with Serious Liver Events among Patients with Type 2 Diabetes Mellitus: A Scandinavian Cohort Study,” Engstom A, Wintzell V, Melbye M, et al.  Hepatology 2024; In Press.

Ustekinumab and Vedolizumab Demonstrate Safety During Pregnancy: Updates from the PIANO Registry
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Rahul Dalal, MD, MPH discuss “Maternal and Neonatal Outcomes in Vedolizumab and Ustekinumab Exposed Pregnancies: Results from the PIANO registry,” by Chugh R, Long MD, Jiang Y, Weaver KN, Beaulieu DB, Scherl EJ, Mahadevan U. Am J Gastroenterol. 2023 Oct 5. Epub ahead of print.   

Issue 28

ESD vs EMR for Large Non-Pedunculated Colon Polyps: Fewer Recurrences but More Complications   
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jeffrey Lee, MD, MPH discuss “Endoscopic En Bloc Versus Piecemeal Resection of Large Nonpedunculated Colonic Adenomas: A Randomized Comparative Trial,” by Jacques J, Schaefer M, Wallenhorst T, et al. Ann Intern Med 2024; 177: 29-38.

ICYMI: Eating “Healthy” to Minimize Colon Cancer
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Association of Ultra-Processed Food Consumption with Colorectal Cancer Risk Among Men and Women,” by Wang L, Du M, Wang K, et al. BMJ 2022; 378:e068921.

When to Discontinue Colorectal Cancer Screening in Older Adults: Chronological Age or Life Expectancy?  
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Philip Okafor, MD, MPH discuss “Colorectal Cancer Screening Receipt Does Not Differ by 10-Year Mortality Risk among Older Adults,” by Liu PH, Singal AG, Murphy CC. Am J Gastroenterol 2024; 119: 353-63.

ICYMI: How Frequently Should We Perform Colonoscopy in Patients with Serrated Polyposis Syndrome?   
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Timothy Yen, MD discuss “Personalised Surveillance for Serrated Polyposis Syndrome: Results from a Prospective 5-Year International Cohort Study,” by Bleijenberg AG, IJspeert JE, van Herwaarden YJ, et al. Gut 2020; 69: 112-21.

Issue 27

Add Prophylactic Pancreatic Duct Stents to Rectal Indomethacin to Minimize Post-ERCP Pancreatitis in High-Risk Patients  
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Joseph Elmunzer, MD, MSc discuss “Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised trial,” by Elmunzer BJ, Foster LD, Serrano J et al. Lancet 2024; 403: 450-58. 

Non-Erosive GERD Does Not Lead to an Increased Risk of Esophageal Adenocarcinoma
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Swathi Eluri, MD, MSCR discuss “Non-erosive gastro-oesophageal reflux disease and incidence of oesophageal adenocarcinoma in three Nordic countries: population based cohort study,” by Holmberg D, Giola S, von Euler-Chelpin M, et al. BMJ 2023; 382: e076017.

Making Bowel Preparation Palatable: Efficacy of a Novel Sports Drink Flavor-Optimized PEG and Sulfate Bowel Preparation
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Ahmad Abu-Heija, MBBS discuss “Comparison of a novel, flavor-optimized, polyethylene glycol and sulfate bowel preparation with oral sulfate solution in adults undergoing colonoscopy,” by Summarizing Bhandari R, Goldstein M, Mishkin DS, et al. J Clin Gastroenterol; 2023;57(9):920-927.

Continued Treatment With Tirzepatide Is Necessary to Maintain Weight Loss
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Sonali Paul, MD discuss “Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial,” by Aronne LJ, Horn DB, Bays HE, et al. JAMA 2024; 3310: 38-48.

Issue 26

Mirikizumab Is Effective for Induction and Maintenance of Ulcerative Colitis
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Rahul Dalal, MD, MPH discuss “Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis,” by D’Haens G, Dubinsky M, Kobayashi T, et al. N Engl J Med. 2023 Jun 29;388(26):2444-2455.

Is Early Ileocecal Resection for Crohn’s Disease An Appropriate Primary Treatment? 
Philip Schoenfeld, MD, MSEd, MSc and Bharati Kochar, MD, MS discuss “Early Ileocecal Resection for Crohn’s Disease is Associated with Improved Long-Term Outcomes Compared with Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study,” by Agrawal M, Ebert AC, Poulsen G, et al. Gastroenterology 2023; 165:976-985.

Which Endoscopists Benefit from Using Computer-Aided Detection of Polyps During Colonoscopy?
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Endoscopist-Level and Procedure-Level Factors Associated with Increased Adenoma Detection With the Use of a Computer-Aided Detection Device,” by Shaukat A, Lichtenstein DR, Chung DC, et al. Am J Gastroenterol 2023; 118: 1891-94.

Post-Colonoscopy Colorectal Cancer Due to Missed Polyps in Proximal Colon or Rectum with Sub-Optimal Bowel Cleansing
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jeffrey Lee, MD, MPH discuss“Root-cause Analysis of 762 Danish Post-colonoscopy Colorectal Cancer Patients,” by Troelsen FS, Sørensen HT, Pedersen L, Brix LD, Grode LB, Dekker E, Erichsen R. Clin Gastroenterol Hepatol. 2023 Nov;21(12):3160-3169.e5. Epub 2023 Apr 7.

Issue 25

Overt Evidence for the Efficacy and Safety of Thalidomide in Gastrointestinal Bleeding from Small Intestinal Angiodysplasia
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Philip Okafor, MD, MPH discuss “Thalidomide for Recurrent Bleeding Due to Small Intestinal Angiodysplasia,” by Chen H, Wu S, Tang M et al. N Engl J Med 2023 Nov 2;389(18):1649-1659.

Low-dose Tricyclic Antidepressants for Irritable Bowel Syndrome: Definitive Evidence of Benefit from ATLANTIS
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in Primary Care (ATLANTIS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial,” by Ford AC, Wright-Hughes A, Alderson S, et al. Lancet 2023; 402: 1773-85.

Hepatocellular Carcinoma Incidence Rates Are 2%-3% in US Patients with Cirrhosis Regardless of Etiology
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Nicole Rich, MD, MSCS discuss “Incidence and risk factors for hepatocellular carcinoma in cirrhosis: the multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) study,” by Reddy KR, McLerran D, Marsh T et al. Gastroenterology 2023; 165(4): 1053-1063.e6.

ICYMI: Lynch Syndrome-An Aspirin a Day Keeps Colorectal Cancer Away!
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Swati Patel, MD, MS discuss “Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial,” by Burn J, Sheth H, Elliot F, et al. Lancet 2020;395:1855-63.

Issue 24

Etrasimod, a Sphingosine 1-Phosphate Receptor Modulator, for Moderate-Severe Ulcerative Colitis: New Options for Oral Therapy
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Rahul Dalal, MD, MS discuss “Etrasimod as Induction and Maintenance Therapy for Ulcerative Colitis (ELEVATE): Two Randomised, Double-Blind, Placebo-Controlled, Phase 3 Studies,” by Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Lancet 2023; 401: 1159-71.

Post-Endoscopy Esophageal adenoCarcinoma: Take a PEEC at Endoscopy Quality in Barrett’s Esophagus
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jennifer Kolb, MD, MPH discuss “Magnitude and Time-Trends of Post-Endoscopy Esophageal Adenocarcinoma and Post-Endoscopy Esophageal Neoplasia in a Population-Based Cohort Study: The Nordic Barrett’s Esophagus Study,” by Wani S, Holmberg D, Santonin G, et al. Gastroenterology 2023; 165:909-19.

Surveillance of Branch Duct IPMN – Enough is Enough, At Least in Older Adults and Small, Stable Lesions
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Shria Kumar, MD, MSCE discuss “Surveillance for Presumed BD-IPMN of the Pancreas: Stability, Size, and Age Identify Targets for Discontinuation,” by Marchegiani G, Pollini T, Burelli A, et al. Gastroenterology 2023 Oct;165(4):1016-1024.e5

GI Adverse Events with GLP-1 Agonists for Weight Loss: Understanding the Risks
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Sonali Paul, MD, MS discuss “Risk of Gastrointestinal Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss,” by Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. JAMA Medicine 2023; In Press.

Issue 23

The New Frontier of Combination Therapy for IBD: The VEGA RCT
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Bharati Kochar, MD, MS discuss “Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial,” by Feagan BG, Sands BE, Sandborn WJ, et al. Lancet Gastroenterology & Hepatology 2023; 8: 307-20.

ICYMI: Biosimilar BI 695501 Has Similar Safety and Efficacy to Adalimumab for the Treatment of Crohn’s Disease: VOLTAIRE-CD Study
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Rahul Dalal, MD, MPH discuss “Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn’s disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial,” by Hanauer S, Liedert B, Balser S, et al. Lancet Gastroenterol Hepatol. 2021 Oct;6(10):816-825. Epub 2021 Aug 11.

Hepatitis C Virus Testing and Treatment – A Call To Action
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Sonali Paul, MD, MS discuss “Hepatitis C Treatment Initiation Among US Medicaid Enrollees,” by Kapadia SN, Zhang H, Gonzalez CJ, et al. JAMA Netw Open. 2023 Aug 1;6(8):e2327326.

PPIs are NOT Associated with Dementia: Refuting Sensational Claims in a Post-Modern Epidemiologic Era
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Association of Proton Pump Inhibitor Use with Incident Dementia and Cognitive Decline in Older Adults: A Prospective Cohort Study,” by Mehta R, Kochra B, Zhou Z, et al. Gastroenterology 2023; 165: 564-72. 

Issue 22

Time To Simplify ADR Calculation for Colonoscopy Quality Reporting  
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jeffrey Lee, MD, MPH discuss “Evaluating Different Approaches for Calculating Adenoma Detection Rate: Is Screening Colonoscopy the Gold Standard?” by Corley DA, Jensen CD, Chubak J, Schottinger JE, Halm EA, Udaltsova N. Gastroenterology. [2023 Sep;165(3):784-787.e4].

Cannabidiol: A Potential Therapeutic Option for Idiopathic and Diabetic Gastroparesis
Philip Schoenfeld, MD, MSEd, MSc (Epi), Philip Okafor, MD, MPH, and Linda Nguyen, MD discuss “A Randomized Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis,” by Zheng T, BouSaba J, Taylor A et al. Clinical Gastroenterology and Hepatology [2023 Jul 22;S1542-3565(23)00543-8].

American College of Physicians Guidance Statement on Colorectal Cancer Screening: Pitfalls of Second-Guessing Guidelines
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement from the American College of Physicians (Version 2),” by Qaseem A, Harrod CS, Crandall CJ, et al. Annals of Internal Medicine [2023; 176: 1092-1100].

Long Road to Achieving Competence in Cold Snare Polypectomy: Video-Based Feedback Can Help!
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Swati Patel, MD, MS discuss “Varied Trainee Competence in Cold Snare Polypectomy – Results of the COMPLETE Randomized Controlled Trial,” by Kaltenbach T, Patel SG, Nguyen-Vu T, Malvar C, Keswani RN, Hall M, Aagaard E, Asokkumar R, Chin YK, Hammad H, Rastogi A, Shergill A, Simon V, Soetikno A, Soetikno R, Wani S. Am J Gastroenterol. [2023 Jun 13].

Issue 21

“Cooking Up Something New” with a One-Food Elimination Diet: A Simpler Approach to Dietary Therapy for Eosinophilic Esophagitis
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jennifer Kolb, MD, MS discuss “One-food versus six-food elimination diet therapy for the treatment of eosinophilic esophagitis: a multicenter, randomized, open-label trial,” by Kliewer K, Gonsalves N, Dellon E, et al. Lancet Gastro Hepatol [2023; 8: 408-21].

Kiwifruit-A Specific Food To Improve Stool Frequency in Patients with Mild Constipation
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Consumption of 2 Green Kiwifruits Daily Improves Constipation and Abdominal Comfort-Results of an International Multicenter Randomized Controlled Trial,” Gearry R, Fukudo S, Barbara G, et al. Am J Gastroenterol [2023; 118: 1058-68].

ICYMI: Albumin Infusions Do Not Improve Outcomes in Hospitalized Patients with Decompensated Cirrhosis-The ATTIRE Trial
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Nicole Rich, MD, MSCS discuss “A randomized trial of albumin infusions in hospitalized patients with cirrhosis,” by China L, Freemantle N, Forrest E et al. NEJM [2021; 384: 808-817].

Surveillance Colonoscopy Recommendations in Older Adults With Limited Life Expectancy– More Work to be Done!
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Shria Kumar, MD, MSCE discuss “Association of Life Expectancy With Surveillance Colonoscopy Findings and Follow-up Recommendations in Older Adults,” by Calderwood AH, Tosteson TD, Wang Q, et al. JAMA Intern Med. [2023 May 1;183(5):426-34].

Issue 20

Upadacitinib Is Effective for the Induction and Maintenance of Moderate-to-Severe Crohn’s Disease
Rahul Dalal, MD, MPH and Jessica Allegretti, MD, MPH discuss “Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease,” by Loftus EV Jr, Panés J, Lacerda AP, Peyrin-Biroulet L, et al. N Engl J Med [2023 May 25;388(21):1966-1980].

Vedolizumab: An EARNEST Option for the Management of Chronic Pouchitis
Kristin Burke, MD, MPH and Bharati Kochar, MD, MS discuss “Vedolizumab for the Treatment of Chronic Pouchitis,” by Travis S, Silverberg MS, Danese S, et al for the EARNEST Study Group. N Engl J Med [2023 Mar 30;388(13):1191-1200].

Bariatric Surgery Is Superior to Lifestyle Changes + Best Medical Care for Metabolic Dysfunction-Associated Steatohepatitis: The BRAVES Study
Yichin Fu, MD; Sonali Paul, MD, MS discuss “Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial,” by Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Lancet [2023 May 27;401(10390):1786-1797].

Colonoscopy for Colon Polyp Surveillance: Avoid Recommending Early Surveillance
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Real-World Compliance with the 2020 US Multi-Society Task Force on Colorectal Cancer Polypectomy Surveillance Guidelines: An Observational Study,” by Dong J, Wang LF, Ardolino E, Feuerstein J. Gastrointest Endosc [2023; 97:350-56].

Issue 19

Free Online Program Improves Adenoma Detection Rate and Decreases Post-Colonoscopy Colorectal Cancer
Jeffrey Lee, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Impact of a Scalable Training Program on the Quality of Colonoscopy Performance and Risk of Post-Colonoscopy Colorectal Cancer,” by Corley DA, Jensen CD, Lee JK, et al. Gastrointest Endosc [2023; In Press].

Screening Colonoscopy in the Elderly Population-Is Less Better?
Philip Okafor, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Frequency of Use and Outcomes in Individuals Older than 75 Years,” by El Halabi J, Burke CA, Hariri E, et al. JAMA Internal Medicine [2023; 183: 513-19].

Cephalosporins and Ciprofloxacin Still Appropriate First-Line Treatment for Spontaneous Bacterial Peritonitis   
Jacqueline Gaulin (GastroGirl) and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Response-Guided Therapy with Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Validation Study of 2021 AASLD Practice Guideline for SBP,” by Yim HJ, Kim TH, Suh SJ, et al. Am J Gastroenterol [2023; 118: 654-63].

AGA-ACG Clinical Practice Guideline on Chronic Idiopathic Constipation Treatments: Parsing Benefits and Risks Jacqueline Gaulin (GastroGirl) and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “AGA-ACG Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation,” by Chang L, Chey WD, Imdad A, et al. Am J Gastroenterol [2023; 118: 936-54].

Issue 18

Disposable Elevator Caps for Duodenoscopes Decrease Persistent Bacterial Contamination Without Hindering Technical ERCP Performance: The ICECAP Trial
Shria Kumar, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Effect of Disposable Elevator Cap Duodenoscopes on Persistent Microbial Contamination and Technical Performance of Endoscopic Retrograde Cholangiopancreatography: The ICECAP Randomized Clinical Trial,” by Forbes N, Elmunzer BJ, Allain T, et al. JAMA Intern Med [2023;183(3):191-200].

Over-the-Scope Clips Decrease Non-Variceal Upper GI Bleeding vs Standard Endoscopic Treatment… In the Right Patient
Jennifer Kolb, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Comparison of Over-the-Scope Clips to Standard Endoscopic Treatment as the Initial Treatment in Patients With Bleeding From a Nonvariceal Upper Gastrointestinal Cause: A Randomized Controlled Trial,” by Lau JYW, Li R, Tan C et al. Ann Intern Med [2023 Apr;176(4):455-462].

Prophylactic Antibiotics Do Not Improve Mortality in Severe Alcoholic Hepatitis Treated with Corticosteroids
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discusses “Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis,” by Louvet A, Labreuche J, Dao T, et al. JAMA [2023; 329 (18): 1558-66].

Issue 17

SEAVUE: a Sea of Change in Biologic Positioning for Crohn’s Disease
Bharati Kochar, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial,” by Sands BE, Irving PM, Hoops T, et al. Lancet [2022;399(10342):2200-2211].

ICYMI: Vedolizumab Is Superior to Adalimumab for Clinical Remission and Endoscopic Improvement of Ulcerative Colitis-The VARSITY RCT  

Jessica Allegretti, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis,” by Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S. N Engl J Med [2019 Sep 26;381(13):1215-1226].

Vibrating Capsules for Chronic Constipation: The New Non-Pharmacologic Approach
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discusses “Randomized Placebo-Controlled Phase 3 Trial of Vibrating Capsule for Chronic Constipation,” by Rao S, Quigley EMM, Chey WD, et al. Gastroenterology [2023].

ICYMI: Can we prevent hepatic decompensation? Most likely, with nonselective beta blockers.  
Sonali Paul, MD, MS, and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomized, double-blind, placebo-controlled, multicenter trial,” by Villanueva C, Albillos A, Genescà J, et al. Lancet [2019, Apr 20;393(10181):1597-1608]. Erratum in: Lancet [2019 Jun 22;393(10190):2492].

Issue 16

Tumor-based screening for Lynch Syndrome: Check Every Colorectal Cancer  
Swati G. Patel, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “A Canadian Provincial Screening Program for Lynch Syndrome,” by Stone JK, Winter R, Khan D, Rothenmund H, Klein J, Chodirker B, Wightman R, Kim CA, Nugent Z, Singh H. American Journal of Gastroenterology [2023;118:345-53].

What are the Causes of Post-colonoscopy Colorectal Cancer?  
Jeffrey Lee, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Post-Colonoscopy Colorectal Cancer Etiologies in a Large Integrated US Health Care Setting,” by Leung LJ, Lee JK, Merchant SA, Jensen CD, Alam A, Corley DA. Gastroenterology [2022. PMID: 36462551].

10-Year Intervals After Normal Screening Colonoscopy: It’s Not Too Long with High-Quality Colonoscopy
Philip Okafor MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Prevalence of Colorectal Neoplasia 10 or More Years After A Negative Screening Colonoscopy in 120,000 Repeated Screening Colonoscopies,” by Heisser T, Kretschmann J, Hagen B, et al. JAMA Intern Med [2023; 183: 183-90].

Cold Snare Decreases Post-Polypectomy Bleeding vs Hot Snare for Small (< 10mm) Polyps
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discusses “Cold Versus Hot Snare Polypectomy for Small Colorectal Polyps: A Pragmatic Randomized Controlled Trial,” by Chang LC, Chang CY, Chen CY, et al. Ann Intern Med [2023; In Press].

Issue 15

Dupilumab, an IgG4 Monoclonal Antibody, for Eosinophilic Esophagitis: Revising the Treatment Paradigm
Afrin Kamal, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis,” by Dellon ES, Rothenber MH, Collins I, et al. N Engl J Med [2022; 387: 2317-30].

Endoscopic Sleeve Gastroplasty Is Effective for Patients with Obesity Who MERIT Intervention  
Jennifer Kolb, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Endoscopic Sleeve Gastroplasty for Treatment of Class 1 and 2 Obesity (MERIT), a Prospective, Multicentre, Randomised Trial,” by Dayyeh BKA, Bazerbachi F, Vargas EJ, et al. Lancet [2022; 400: 441-51].

Early Colonoscopy for Acute Lower GI Bleeding Usually Is Not the Answer
Shria Kumar, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACGdiscuss “Timing of Colonoscopy in Acute Lower GI Bleeding: A Multicenter Retrospective Cohort Study,” by Shiratori Y, Ishii N, Tomonori A, et al. Gastrointest Endosc [2023; 97: 89-99].

Direct-Acting Antiviral Therapy for Hepatitis C Virus Decreases All-Cause Mortality and Decompensated Cirrhosis: Treat (Virtually) Everyone
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “Association of Direct-Acting Antiviral Therapy with Liver and Nonliver Complications and Long-term Mortality in Patients with Chronic Hepatitis C,” by Ogawa E, Chien N, Kam L, et al. JAMA Internal Medicine [2023; 183: 97-105].

Issue 14

Risankizumab, an Interleukin-23 Inhibitor, for Moderate-Severe Crohn’s Disease: Advancing Care Beyond Anti-TNF Therapy
Bharati Kochar, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Risankizumab as Induction Therapy for Crohn’s Disease: Results from the Phase 3 ADVANCE and MOTIVATE Induction Trials,” by D’Haens G, Panaccione R, Baert F, et al. Lancet [2022; 399: 2015-30].

Subcutaneous risankizumab is effective and safe for the maintenance of moderate-to-severe Crohn’s disease
Jessica Allegretti, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial,” by Ferrante M, Panaccione R, Baert F, et al.  Lancet [2022 May 28;399(10340):2031-2046].

When It’s Not Acid Reflux: Managing PPI-Resistant GERD Patients Based on Bravo Results
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG and Kristle Lee Lynch, MD discuss “Optimal Wireless Reflux Monitoring Metrics to Predict Discontinuation of Proton Pump Inhibitor Therapy,” by Yadlapati R, Gyawali CP, Masihi M, et al. Am J Gastroenterol [2022 Oct 1;117(10):1573-1582]. [Note: This podcast was updated on February 3, 2023 to include a discussion with Dr Kristle Lee Lynch.]

ICYMI: Is Terlipressin for the Treatment of Hepato-Renal Syndrome Ready for Primetime: Results of the CONFIRM Trial
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG and Sonali Paul, MD, MSdiscuss “Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome,” by Wong F, Pappas SC, Curry KR, et al. N Engl J Med [2021; 384: 818-28].

Issue 13

Ozanimod, a Selective Selective Sphingosine-1-Phosphatase Receptor Modulator, for Moderate-Severe Ulcerative Colitis: Re-Thinking the Top-Down Treatment Algorithm for UC
Oriana Damas, MDand Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Ozanimod for Induction and Maintenance of Ulcerative Colitis,” by Sandborn WJ, Feagan BG, D’Haens G, et al.  N Engl J Med [2021; 385: 1280-91].

Continuing Anti-TNF Agents past 24 Weeks of Pregnancy Associated with Fewer IBD Relapses with No Increase in Adverse Fetal Outcomes
Ahmad Abu-Heija, MBBS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Benefits and Risks Associated with Continuation of Anti-Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease,” by Meyer A, Neumann A, Drouin J, et al. Ann Intern Med [2022; 175(10) 1374-82].

RBX2660, a Donor Stool Product for Fecal Microbiota Transplant, Decreases Recurrent Clostridioides difficile Infection: The First FDA-Approved Live Biotherapeutic Product
Collen R. Kelly, MD and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection,” by Khanna S, Assi M, Lee C. et al. Drugs [2022; 82: 1527-1538].

NSAID Use and the Risk of IBD Exacerbations: Fact or Fiction
Philip Okafor, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “The Association Between Nonsteroidal Anti-Inflammatory Drug Use and Inflammatory Bowel Disease Exacerbations: A True Association or Residual Bias?” by Cohen-Mekelburg S, Van T, Wallace B, et al. Am J Gastroenterol [2022; 117 (11): 1851-57].

Issue 12

ICYMI: Surgery is Superior to Medical Therapy for PPI-Refractory Heartburn in the “Right” Patients
Jennifer Kolb, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn,” by Spechler SJ, Hunter JG, Jones KM, et al. N Engl J Med [2019;381:1513-1523].

Vonoprazan, a Potassium-Channel Acid Blocker, is Superior to Lansoprazole for Managing Erosive Esophagitis
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “Vonoprazan versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial,” by Laine L, DeVault K, Katz P, et al. Gastroenterology [2022; In Press].

Reinvestigating the Lack of Association Between Proton Pump Inhibitor Use and Mortality by Accounting for Reverse Causation
Ravy Vajravelu, MD, MSCE andEditor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Association of Proton Pump Inhibitor Use With All-Cause and Cause-Specific Mortality,” by Lo CH, Ni P, Yan Y, et al. Gastroenterology [2022; 163:852 – 61].

Issue 11

Upadacitinib, a Selective JAK1 Inhibitor, for Moderate-Severe Ulcerative Colitis: Adjusting the Top-Down Treatment Algorithm for UC  
Jami Kinnucan, MD and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MSc (Epi) discuss “Upadacitinib as Induction and Maintenance Therapy for Moderately to Severely Active Ulcerative Colitis: Results from Three Phase 3, Multicentre, Double-Blind, Randomised Trials,” by Danese S, Vermeire S, Zhou W, et al, published in Lancet [2022; 399: 2113-28].

Colonoscopy Reduces CRC Incidence and CRC-Related Mortality…. If You Get It!
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death,” by Bretthauer M, Løberg M, Wieszczy P, et al, published in N Engl J Med [Oct 9, 2022].

High Adenoma Detection Rate Decreases Post-Colonoscopy CRC in FIT-Based Screening Program: Quality Matters!
Joseph Sleiman, MD and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MSc (Epi) discuss “Adenoma Detection Rate and Risk for Interval Postcolonoscopy Colorectal Cancer in Fecal Immunochemical Test-Based Screening: A Population-Based Cohort Study,” by Wisse PHA, Erler N, de Boer SY, et al, published in Ann Intern Med [2022; In Press].

Acute pancreatitis: Need IV fluid resuscitation but avoid a WATERFALL!
Shria Kumar, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis,” by de-Madaria E, Buxbaum JL, Maisonneuve P, et al, published in N Engl J Med [2022;387(11):989-1000].

Issue 10

Time to Increase Adenoma Detection Rate Benchmarks for Screening Colonoscopies 
Jeffrey Lee, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Association of Physician Adenoma Detection Rates With Postcolonoscopy Colorectal Cancer,” by Schottinger JE, Jensen CD, Ghai NR, et al, published in JAMA [2022 Jun 7;327(21):2114-2122].

Continue Thiopurines and Anti-TNF Agents If Your IBD Patient Becomes Pregnant
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease,” by Mahadevan U, Long MD, Kane SV, et al, published in Gastroenterology [2021 Mar;160(4):1131-1139].

Achieve IBD Remission Before Pregnancy: PIANO Registry Data Shows Adverse Perinatal Outcomes For Infants Associated with IBD Flares and Steroid Use

Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “Exposure to Corticosteroids in Pregnancy Is Associated with Adverse Perinatal Outcomes Among Infants of Mothers with Inflammatory Bowel Disease,” by Odufalu FD, Long MD, Lin K, Mahadaven U for PIANO Investigators, published in GUT [2022; 71: 1766-72].

ICYMI-Pantoprazole Prophylaxis Does Not Reduce 90-day Mortality and Clinically Significant Adverse Events in ICU Patients
Philip Okafor, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Pantoprazole in Patients at Risk for Gastrointestinal for Gastrointestinal Bleeding in the ICU,” by Krag M, Marker S, Perner A et al, published in NEJM [379; 23: 2018].

Issue 9

ADR Isn’t the Only Game in Town: Proximal Serrated Lesion Detection Rates Are Inversely Associated with Post-Colonoscopy Cancer Risk

Swati Patel, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Serrated polyp detection and risk of interval post-colonoscopy colorectal cancer: a population-based study,” by van Toledo et al, published in Lancet Gastroenterol Hepatol [2022 Aug;7(8):747-754]. https://pubmed.ncbi.nlm.nih.gov/35550250/

Tiny Polyps-It’s OK to Remove Polyps < 3mm with Large Biopsy Forceps

Shria Kumar, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Randomized Controlled Trial Investigating Cold Snare and Forceps Polypectomy Among Small POLYPs in Rates of Complete Resection: The TINYPOLYP Trial,” by Wei et al, published in Am J Gastroenterol [2022 Aug 1;117(8):1305-1310]. https://pubmed.ncbi.nlm.nih.gov/35467557/

Prophylactic Rifaximin Decreases Post-TIPS Hepatic Encephalopathy 

Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial,” by Bureau et al, published in Ann Intern Med [2021 May;174(5):633-640].https://pubmed.ncbi.nlm.nih.gov/33524293/

Issue 8

Treating H.pylori Infection with Vonoprazan, a Potassium-Competitive Acid Blocker: A New Paradigm

Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the US and Europe: A Randomized Controlled Trial,” by Chey, et al, published in Gastroenterology [2022; In Press]. https://pubmed.ncbi.nlm.nih.gov/35679950/

In Case You Missed It: Peroral Endoscopic Myotomy (POEM) for Achalasia: At Least As Good as Laparoscopic Heller’s Myotomy

Jennifer Kolb, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Endoscopic or Surgical Myotomy in Patients with Idiopathic Achalasia,” by Werner et al, published in N Engl J Med [2019;381:2219-2229]. https://pubmed.ncbi.nlm.nih.gov/31800987/

Does Choice of Anticoagulant Influence Risk of Gastrointestinal Bleeding? 

Ravy K. Vaajravelu, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants : A Nationwide Propensity Score-Weighted Study,” by Ingason et al, published in Ann Intern Med [2021 Nov;174(11):1493-1502]. https://pubmed.ncbi.nlm.nih.gov/34633836/

Adenoma Detection Rate in 45-49 Year Olds is Lower Compared to 50-54 Year Olds, but Still Higher than 25% Benchmark

Philip Okafor, MD and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Adenoma Detection Rates in 45-49-Year-Old Persons Undergoing Screening Colonoscopy: Analysis From the GIQuIC Registry,” by Bilal et al, published in Am J Gastroenterol [2022 May 1;117(5):806-808]. https://pubmed.ncbi.nlm.nih.gov/35169107/

Issue 7

SER-109, an Oral Microbiome Therapy, Decreases Recurrent Clostridiodes difficile Infection 

Jessica Allegretti, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection” by Feuerstadt et al, published in N Engl J Med [2022;386(3):220-229]. https://pubmed.ncbi.nlm.nih.gov/35045228/

When Is Routine Prophylactic Clipping Indicated Post-Polypectomy?

Jeffrey Lee, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Effect of prophylactic endoscopic clip placement on clinically significant post-endoscopic mucosal resection bleeding in the right colon: a single-centre, randomised controlled trial” by Gupta et al, published in Lancet Gastroenterol Hepatol [2022;7(2):152-160]. https://pubmed.ncbi.nlm.nih.gov/34801133/

Tenapanor (IBSRELA) for Treatment of IBS-C: Effective over 26 Weeks

Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome with Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)” by Chey et al, published in Am J Gastroenterol [2021;116: 1294-1303]. https://pubmed.ncbi.nlm.nih.gov/33337659/

Issue 6

Low Grade Dysplasia in Barrett’s Esophagus – Get Two Expert GI Pathologist Reviews and Repeat EGD After PPI Treatment

Shria Kumar, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Discordance Among Pathologists in the United States and Europe in Diagnosis of Low-Grade Dysplasia for Patients With Barrett’s Esophagus” by Vennalaganti et al, published in Gastroenterology [2017 Feb;152(3):564-570.e4]. https://pubmed.ncbi.nlm.nih.gov/27818167/

Issue 5

Therapeutic Drug Monitoring of Maintenance Infliximab Is Beneficial for Patients with Immunemediated Inflammatory Diseases

Jessica R. Allegretti, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial” by Syversen et al, published in JAMA [2021; 326(23):2375-2384]. https://pubmed.ncbi.nlm.nih.gov/34932077/

Endoscopic Eradication Therapy for Neoplastic Barrett’s Esophagus Demonstrates 94% Treatment Success and Long-term Durability

Jennifer M Kolb MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Long-term Outcomes after Endoscopic Treatment for Barrett’s Neoplasia with Radiofrequency Ablation ± Endoscopic Resection: Results from the National Dutch Database in a 10-year Period” by Munster et al, published in Gut [2022;71:265-76]. https://pubmed.ncbi.nlm.nih.gov/33753417/

Issue 4

Increased Risk of Metachronous Neoplasia After Incomplete Polyp Resection – Time to CARE About Polypectomy Technique!

Jeffrey Lee, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Recurrence of Colorectal Neoplastic Polyps After Incomplete Resection” by Pohl et al, published in Annals of Internal Medicine. [2021;174(10):1377-1384]. https://pubmed.ncbi.nlm.nih.gov/34370514/

It’s a Bad “Prep” Even Though the Patient Took It Correctly: Consider 15 mg Bisacodyl plus 4-Liter PEG Split Prep Before Next Colonoscopy

Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “A Multicenter Randomized Controlled Trial Comparing Bowel Cleansing Regimens for Colonoscopy After Failed Bowel Preparation” by Sey at al, published in Clinical Gastroenterology and Hepatology [2022;In Press]. https://pubmed.ncbi.nlm.nih.gov/34256147

Effectiveness of Intermittent Fasting for Weight Loss: It’s Not Just When You Eat, but What You Eat, Too!

Sonali Paul, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men with Overweight and Obesity. The TREAT Randomized Clinical Trial” by Lowe et al, published in JAMA [2021; 181(6):883]. https://pubmed.ncbi.nlm.nih.gov/32986097/

Family Matters: Increased Risk of Colorectal Cancer among Individuals with Family History of Polyps

Ravy K. Vajravelu, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Risk of colorectal cancer in first degree relatives of patients with colorectal polyps: nationwide case-control study in Sweden” by Song et al, published in BMJ [2021;373:n877]. https://pubmed.ncbi.nlm.nih.gov/33947661/

Issue 3

Slow Down to Speed Up Quality: Longer Withdrawal Time of 9 Versus 6 Minutes Increases Adenoma Detection Rate

Jennifer M. Kolb MD, MSCS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi, FACG discuss “Impact of 9-Minute Withdrawal Time on the Adenoma Detection Rate: A Multicenter Randomized Controlled Trial” by Zhao et al, published in Clinical Gastroenterology and Hepatology [2020;20:31553-6]. https://pubmed.ncbi.nlm.nih.gov/33220526/

Drainage for Infected Pancreatic Necrosis – Earlier Is Not Better

Shria Kumar, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi, FACG discuss “Immediate versus Postponed Intervention for Infected Necrotizing Pancreatitis” by Boxhoorn et al, published in NEJM. [2021;15:1372-1381]. https://pubmed.ncbi.nlm.nih.gov/34614330/

Hereditary Syndrome Risk Assessment in all Colorectal Cancer Patients: Keep it Simple!

Swati Patel, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi, FACG discuss “Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative” by Pearlman et al, published in JCO Precision Oncology [2021;5:779-91]. https://pubmed.ncbi.nlm.nih.gov/34250417/

Treating All the Symptoms of IBS-C: Linaclotide Significantly Decreases Abdominal Pain, Bloating, and Discomfort

Jill Deutsch, MD and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi, FACG discuss “Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System” by Chang et al, published in American Journal of Gastroenterology [2021;116: 1929-37]. https://pubmed.ncbi.nlm.nih.gov/34465695/

Issue 2

A New “Pill Prep” for Colonoscopy: An Effective Alternative for Individuals Who Won’t Drink GoLytely®

Philip N. Okafor, MD, MPH discusses the recent AJG article “A Safety and Efficacy Comparison of a New Sulfate-Based Tablet Bowel Preparation Versus a PEG and Ascorbate Comparator in Adult Subjects Undergoing Colonoscopy.” This RCT compares SUTAB®, a sodium sulfate tablet bowel preparation, to MoviPrep®. Since it is a hyperosmolar prep, be cautious when using it in patients with congestive heart failure, renal insufficiency, or electrolyte abnormalities.

Inching Closer to a NASH Cure: Daily Semaglutide Achieves Resolution of NASH but Not Fibrosis after 72 Weeks

Sonali Paul, MD, MS discusses “A Placebo-Controlled Trial of Subcutaneous Semaglutide,” published in NEJM in May 2021. Semaglutide, a GLP-1 receptor agonist for type II diabetes mellitus and weight loss, shows potential as a treatment for NASH in a well-designed, placebo-controlled RCT. May need longer trials to see if it can resolve fibrosis, which is a key treatment goal. Will anxiously await results from ongoing study of weekly high-dose semaglutide in NASH patients.

Computer-aided Detection Systems increase detection of non-advanced adenomas, but is it ready for prime-time?

Shria Kumar, MD, MSCE discusses a 2020 article in Gastroenterology, “Efficacy of Real-Time Computer-Aided Detection of Colorectal Neoplasia in a Randomized Trial.” GI-Genius™, a new computer-aided adenoma detection tool, is FDA-approved, integrates into existing endoscopic systems, and overlays a detection box around a potential polyp. In a well-designed RCT, adenoma detection was significantly higher with GI-Genius™. Endoscopists will need to consider a variety of factors to determine whether to integrate this tool into their endoscopy practice.

Issue 1

Piecemeal Cold Snare Polypectomy of Large SSP: Cold Is the New Hot

Swati Patel, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi, FACG discuss Piecemeal cold snare polypectomy versus conventional endoscopic mucosal resection for large sessile serrated lesions: a retrospective comparison across two successive periods bt Van Hattem WA, published in Gut [2021;70:1691-97]. https://doi.org/10.1136/gutjnl-2020-321753

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Sonali Paul, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi, FACG discuss Semaglutide Treatment Effect in People with Obesity (STEP) Investigators. Once-Weekly Semaglutide in Adults with Overweight or Obesity by Wilding et al, published in the New England Journal of Medicine [2021; 384: 989-1002. https://www.nejm.org/doi/10.1056/NEJMoa2032183

Screening Colonoscopy Decreases Colorectal Cancer Incidence and Related Mortality in Healthy Patients Over 75

Jeffrey Lee, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi, FACG discuss Association of Screening Lower Endoscopy with Colorectal Cancer Incidence and Mortality in Adults Older than 75 Years by Ma et al, published in .JAMA Oncology [2021;7(7):985-992]. https://doi.org/10.1001/jamaoncol.2021.1364

Acute Myeloid Leukemia and Myelodysplastic Syndrome with IBD and Thiopurines Impact on Risk

Ravy K. Vajravelu, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi, FACG discuss Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients with Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk by Kahn et al., published in The American Journal of Gastroenterology [2021; 116: 741-47]. www.doi.org/10.14309/ajg.0000000000001058